Subscribe to RSS
Primary Bone Lymphoma: An Experience of a Regional Cancer Center from IndiaFundingNone.
Background Primary bone lymphoma (PBL) is a rare disease, representing <5% of all extranodal non-Hodgkin’s lymphomas (NHLs). The optimal treatment strategy is still unclear. Here, we report our institutional outcome analysis of patients diagnosed with PBL.
Materials and Methods From 2007 to 2014, the medical records of 22 patients with PBL were reviewed. Analysis was done for symptom-, patient-, disease-, and treatment-related characteristics. All patients were treated with chemotherapy with or without radiotherapy. Treatment response and impact of different prognostic factors on clinical outcome were analyzed.
Results The median age of presentation was 44 years (range: 18–70 years). A total of 19 (86.4%) patients were ≤60 years of age and 3 (13.6%) patients were >60 years. Out of all, 18 were males and 4 were females. Ann Arbor clinical staging at diagnosis was Stage I in 13 (59.1%), Stage II in 3 (13.6%), Stage III in 2 (9.1%), and Stage IV in 4 (18.2%) patients. Spine was the most common site of involvement seen in 12 (54.5%) patients. Diffuse large B cell lymphoma histology was seen in 8 (36.4%) patients and 8 (36.4%) had high-grade NHL. Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone was given to 20 (90.9%) patients, whereas 2 (9.1%) patients received cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab. Radiotherapy (30-40 Gy) was delivered to 19 (86.4%) patients. The median follow-up period was 40 months (range: 8–105 months). The overall response rate was 86.3% with complete response (CR) in 15 (68.1%) and partial response in 4 (18.2%) patients. Relapses were seen in three (13.5%) patients: two nodal, and one in the bone. Disease-free survival (DFS) and overall survival (OS) at 5 years were 56.6 and 72.7%, respectively. CR after initial treatment was associated with a significant better OS, 80 and 25%, respectively (p < 0.0001). Age, sex, stage, International Prognostic Index, histologic subtype, and number of sites had no significant influence on OS. Combining radiation therapy with chemotherapy (with or without rituximab) also did not improve the OS or DFS of patients.
Conclusion In spite of small number of patients reported in this study, conventional chemotherapy remains an effective treatment option for patients with PBL. OS was found to be affected by the initial response to treatment.
12 June 2021 (online)
© 2020. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Thieme Medical and Scientific Publishers Private Ltd
A-12, Second Floor, Sector -2, NOIDA -201301, India
- 1 Dubey P, Ha CS, Besa PC. et al. Localized primary malignant lymphoma of bone. Int J Radiat Oncol Biol Phys 1997; 37 (05) 1087-1093
- 2 Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology (Am Soc Hematol Educ Program) 2009; 1: 523-531
- 3 Baar J, Burkes RL, Gospodarowicz M. Primary non-Hodgkin’s lymphoma of bone. Semin Oncol 1999; 26 (03) 270-275
- 4 Kim SY, Shin DY, Lee SS. et al. Clinical characteristics and outcomes of primary bone lymphoma in Korea. Korean J Hematol 2012; 47 (03) 213-218
- 5 Ramadan KM, Shenkier T, Sehn LH, Gascoyne RD, Connors JM. A clinicopathological retrospective study of 131 patients with primary bone lymphoma: a population-based study of successively treated cohorts from the British Columbia Cancer Agency. Ann Oncol 2007; 18 (01) 129-135
- 6 Cheson BD, Horning SJ, Coiffier B. et al. NCI Sponsored International Working Group. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. J Clin Oncol 1999; 17 (04) 1244
- 7 Mikhaeel NG. Primary bone lymphoma. Clin Oncol (R Coll Radiol) 2012; 24 (05) 366-370
- 8 Jawad MU, Schneiderbauer MM, Min ES, Cheung MC, Koniaris LG, Scully SP. Primary lymphoma of bone in adult patients. Cancer 2010; 116 (04) 871-879
- 9 Matikas A, Briasoulis A, Tzannou I. et al. Primary bone lymphoma: a retrospective analysis of 22 patients treated in a single tertiary center. Acta Haematol 2013; 130 (04) 291-296
- 10 Maruyama D, Watanabe T, Beppu Y. et al. Primary bone lymphoma: a new and detailed characterization of 28 patients in a single-institution study. Jpn J Clin Oncol 2007; 37 (03) 216-223
- 11 Ueda T, Aozasa K, Ohsawa M. et al. Malignant lymphomas of bone in Japan. Cancer 1989; 64 (11) 2387-2392
- 12 Heyning FH, Hogendoorn PC, Kramer MH. et al. Primary non-Hodgkin’s lymphoma of bone: a clinicopathological investigation of 60 cases. Leukemia 1999; 13 (12) 2094-2098
- 13 Zinzani PL, Carrillo G, Ascani S. et al. Primary bone lymphoma: experience with 52 patients. Haematologica 2003; 88 (03) 280-285
- 14 Beal K, Allen L, Yahalom J. Primary bone lymphoma: treatment results and prognostic factors with long-term follow-up of 82 patients. Cancer 2006; 106 (12) 2652-2656
- 15 Alencar A, Pitcher D, Byrne G, Lossos IS. Primary bone lymphoma–the University of Miami experience. Leuk Lymphoma 2010; 51 (01) 39-49
- 16 Pellegrini C, Gandolfi L, Quirini F. et al. Primary bone lymphoma: evaluation of chemoimmunotherapy as front-line treatment in 21 patients. Clin Lymphoma Myeloma Leuk 2011; 11 (04) 321-325